Cyclopentane

Cyclopentane

SCHEMBL248218

C1CCCC1.c1ncc2[nH]nnc2n1

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 1/20 0.33
METAP1 P53582 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29356966 0.94
SCHEMBL2587704 0.94 METAP2 (0.35) METAP2METAP1
SCHEMBL26606 0.94
SCHEMBL30544002 0.92 METAP2 (0.34) METAP2METAP1
Hydrochloric Acid SCHEMBL5791474 0.92 METAP2 (0.34) METAP2METAP1
Piperidine SCHEMBL28232867 0.91 ALDH1A1 (0.30)
Pyrimidine SCHEMBL3822426 0.85 METAP2 (0.37) METAP2METAP1
Pyridine SCHEMBL28107404 0.83 METAP2 (0.40) METAP2METAP1
Sulfamide SCHEMBL9442883 0.83 METAP2 (0.30) METAP2METAP1
Phenazine SCHEMBL28258542 0.80 EGFR (0.43) METAP2METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3157907-B1 PROCESS FOR THE PREPARATION OF TRIAZOLO[4,5-D]PYRIMIDINE CYCLOPENTANE COMPOUNDS FLAMMA SPA (IT) 2018-08-29 EP claimed
US-10011605-B2 Process for the preparation of triazolo[4,5-D] pyrimidine cyclopentane compounds FLAMMA SPA (IT) 2018-07-03 US claimed
US-20170129898-A1 PROCESS FOR THE PREPARATION OF TRIAZOLO[4,5-D] PYRIMIDINE CYCLOPENTANE COMPOUNDS FLAMMA SPA (IT) 2017-05-11 US claimed
EP-3157907-A1 PROCESS FOR THE PREPARATION OF TRIAZOLO[4,5-D]PYRIMIDINE CYCLOPENTANE COMPOUNDS Flamma S.P.A. (IT) 2017-04-26 EP claimed
WO-2015193165-A1 PROCESS FOR THE PREPARATION OF TRIAZOLO[4,5-D] PYRIMIDINE CYCLOPENTANE COMPOUNDS FLAMMA SPA (IT) 2015-12-23 WO claimed
EP-2480330-B1 A PROCESS AND CATALYST FOR THE CATALYTIC HYDROGENATION OF AROMATIC AND HETEROAROMATIC NITRO COMPOUNDS ASTRAZENECA AB (SE) 2021-05-26 EP disclosed
EP-3157907-B1 PROCESS FOR THE PREPARATION OF TRIAZOLO[4,5-D]PYRIMIDINE CYCLOPENTANE COMPOUNDS FLAMMA SPA (IT) 2018-08-29 EP disclosed
US-10011605-B2 Process for the preparation of triazolo[4,5-D] pyrimidine cyclopentane compounds FLAMMA SPA (IT) 2018-07-03 US disclosed
US-10011605-B2 Process for the preparation of triazolo[4,5-D] pyrimidine cyclopentane compounds FLAMMA SPA (IT) 2018-07-03 US disclosed
US-10011605-B2 Process for the preparation of triazolo[4,5-D] pyrimidine cyclopentane compounds FLAMMA SPA (IT) 2018-07-03 US disclosed
US-20180148745-A1 HEMOPROTEIN CATALYSTS FOR IMPROVED ENANTIOSELECTIVE ENZYMATIC SYNTHESIS OF TICAGRELOR CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2018-05-31 US disclosed
EP-3303267-A2 HEMOPROTEIN CATALYSTS FOR IMPROVED ENANTIOSELECTIVE ENZYMATIC SYNTHESIS OF TICAGRELOR California Institute of Technology (US) 2018-04-11 EP disclosed
WO-2011036479-A2 PROCESS AND CATALYST ASTRAZENECA AB (SE) 2011-03-31 WO disclosed
US-20110071290-A1 Process And Catalyst ASTRAZENECA AB (SE) 2011-03-24 US disclosed
US-20100324289-A1 Chemical Process ASTRAZENECA AB (SE) 2010-12-23 US disclosed
US-7799914-B2 Chemical process ASTRAZENECA AB (SE) 2010-09-21 US disclosed
US-7393962-B2 Chemical process ASTRAZENECA AB (SE) 2008-07-01 US disclosed
US-20070219371-A1 Chemical Process ASTRAZENECA AB (SE) 2007-09-20 US disclosed
US-20070197805-A1 Chemical process ASTRAZENECA AB (SE) 2007-08-23 US disclosed
EP-1732916-B1 PROCESS FOR THE PREPARATION OF ALKOXYCARBONYLMETHOXY-CYCLOPENTANES ASTRAZENECA AB (SE) 2007-07-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197805-A1 Chemical process CBR3, CYP4F3, NOX3 METAP2 4224/4885METAP1 4089/4885
US-20070219371-A1 Chemical Process ADH1C, ADH1A, CBR1 METAP2 3883/4885METAP1 3336/4885
US-20100324289-A1 Chemical Process CBR1, CYP2E1, ADH1C METAP2 3698/4885METAP1 2949/4885
US-20110071290-A1 Process And Catalyst PPOX, NOX5, NUDT1 METAP2 1061/4885METAP1 964/4885
US-10011605-B2 Process for the preparation of triazolo[4,5-D] pyrimidine cyclopentane compounds TBXA2R, THPO, P2RY4 METAP2 3632/4885METAP1 3251/4885
US-20170129898-A1 PROCESS FOR THE PREPARATION OF TRIAZOLO[4,5-D] PYRIMIDINE CYCLOPENTANE COMPOUNDS TBXA2R, THPO, P2RY4 METAP2 3632/4885METAP1 3251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.